Perez de Llano, Luis AlejandroDacal Rivas, DavidMarina Malanda, NuriaPlaza Moral, VicenteGullon Blanco, Jose AntonioMuñoz-Esquerre, MarianaGarcia-Moguel, IsmaelDiaz Campos, Rocio MMartinez-Moragon, EvaHarbenau Mena, AliciaGarcía-Cosío, BorjaPadilla Galo, AliciaCisneros Serrano, Carolina2024-10-042024-10-042022De Llano LP, Rivas DD, Malanda NM, Moral VP, Blanco JAG, Munoz-Esquerre M, et al. The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome. J Asthma Allergy. 2022;15:363-9.1178-6965https://hdl.handle.net/20.500.13003/19867https://hdl.handle.net/20.500.12105/23544Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.enghttp://creativecommons.org/licenses/by/4.0/AsthmaAsthma-COPD overlapCOPDresearch articleAttribution 4.0 International3533078615363-36910.2147/JAA.S338467Journal of Asthma and Allergyopen access2-s2.0-85128300570773456700001L2016373077